Over the past three decades, the goal of many researchers is analysis of exhaled breath condensate (EBC) as noninvasively obtained sample. A total quality in laboratory diagnostic processes in EBC analysis was investigated: pre-analytical (formation, collection, storage of EBC), analytical (sensitivity of applied methods, standardization) and post-analytical (interpretation of results) phases. EBC analysis is still used as a research tool. Limitations referred to pre-analytical, analytical, and post-analytical phases of EBC analysis are numerous, e.g. low concentrations of EBC constituents, single-analyte methods lack in sensitivity, and multi-analyte has not been fully explored, and reference values are not established. When all, preanalytical, analytical and post-analytical requirements are met, EBC biomarkers as well as biomarker patterns can be selected and EBC analysis can hopefully be used in clinical practice, in both, the diagnosis and in the longitudinal follow-up of patients, resulting in better outcome of disease.
Introduction
The main function of the lungs is respiratory function, i.e. respiratory gas exchange. In addition, the lungs have other important non-respiratory functions. The latter include the maintenance of a stable acid-base balance, immunological functions and metabolic activities. Respiratory diseases are the most common diseases in children and adolescents (e.g. allergic diseases, infections of respiratory system) and adults (e.g. chronic obstructive pulmonary disease, COPD). Generally, respiratory diseases include three main groups: airways diseases, lung parenchymal diseases and pulmonary vascular diseases (Figure 1 ).
In some diseases, there is overlap between pathological hallmarks, e.g. allergic alveolitis and emphysema are airways and lung parenchymal diseases; granulomatosis is both, lung parenchymal and pulmonary vascular disease. In industrialized countries, the morbidity of infectious diseases are decreasing, and morbidity of obstructive diseases, particularly asthma and chronic obstructive pulmonary disease (COPD) have been increasing in the past century (1) .
The diagnosis of respiratory diseases and the evaluation of therapeutic outcome are based on history data, clinical symptoms, pulmonary function testing and imaging techniques. In addition, for direct assessment of inflammation invasive procedures to obtain bronchoalveolar lavage (BAL), biopsy specimens, induced sputum are used in everyday practice. However, these procedures are used when strongly indicated, especially in young children (2, 3) . Therefore, over the past three decades, the goal of many researchers has been to approve analysis of breath and exhaled breath condensate (EBC) as noninvasively obtained samples (2, 3 Clinical laboratory specialists should assume responsibility for the total analytical process (total testing cycle) in laboratory medicine, from the patient preparation, test selection, leading to sample collection, transport to the laboratory, sample handling and storage, sample analysis and finally, results report. These activities are classified into three phases -preanalytical, analytical and postanalytical. This paper gives a review of some solved and unsolved problems typical for the total testing cycle of EBC.
Preanalytical phase of EBC analysis
Laboratory professionals are aware that preanalytical phase in laboratory medicine is a very important component of laboratory testing (6, 7) . In the last two decades, a great attention was paid to define preanalytical issues in EBC analysis -from formation, sampling, sample handling, environmental factors, and dilution to appropriate handling and storage (Table 1) .
Formation of EBC
Exhaled breath contains thousands of volatile (such as oxygen, carbon dioxide, nitric oxide, ethane, pentane) and non-volatile compounds, water vapour as well as liquid particles (i.e. droplets) and bioaerosols (bacteria, viruses, fungi) that derive from the respiratory tract (8, 9) . Droplets of respiratory tract lining fluid (RTLF) are released from the surfaces of the airways (Figure 2A ). In addition, a great quantity of water is released as vapour (evaporation). During turbulence in the airways, i.e. during reopening of closed bronchioles and alveoli, non-volatile compound from epithelial lining fluid undergoes aerosolization (3, 10) . The droplet formation depends on the velocity of the flow of exhaled air and the surface tension (higher velocity/lower surface tension). The number of particles in exhaled air is very low, ranging from 0.1 -4 particles x cm -3 (diameter < 0.3 μm) (11 
Collection of EBC
Optimized collectors for EBC sampling are available from various manufacturers, all based on the principle of "freezing exhaled breath" ( Figure 2B ). 
Influence of environmental temperature and relative humidity
Environmental conditions, i.e. relative humidity (RH) and temperature may influence on the volume of EBC and on the determination of some constituents in EBC sample (pH-values). Smaller volume may be obtained at lower RH (19) . RH of inspired air influences the rate at which EBC is formed ( let (21) . The diameter of exhaled particles is smaller and supersaturated at lower ambient RH. Ambient temperature affects significantly the pH-values of EBC. pH is more acidic at 23 o C than at 37 o C (22) . Therefore ambient temperature RH have to be under control in the room, where the EBC is collected.
Collection time of EBC
Ventilatory rate is the major determinant of the amount of EBC over time. With respiratory rate of 15-20 breaths/minute, sufficient sample may be collected during 10-15 minutes (i.e. 150-300 breat hs).
Volume of EBC
A strong positive correlation was found between EBC volume and total respired volume and tidal volume, respectively (23) . Volume of collected EBC does not depend on lung function parameters, e.g. forces expiratory volume in 1 second, (FEV1).
As the amount of EBC increases significantly with higher minute ventilation (19) , the volume of EBC varies among individuals. According to Lema et al. (24) the relation between the volume of inhaled air and the volume of collected EBC for each subject is expressed by the equation:
volume of EBC (mL) = 0.013 × volume of inhaled air (L) + 0.255 (24) .
If respiratory rate remains constant during EBC collection, EBC volume increases linearly with the time of collection. Approximately 1-2 mL of EBC may be collected during the period of about 10 minutes (from 40 to 300 mL/min, average ~100 mL/min) (17) .
Dilution of EBC
EBC contains droplet with large amounts of water vapour and traces of non-volatile solutes. Dilution of EBC is much greater than dilution of RTLF (25), since RTLF is diluting during condensation ( Figure  2B ). Although some methods have been developed to estimate the degree of EBC dilution, i.e. determination of urea, total cation concentration and of conductivity of lyophilized EBC (26), the exact degree of EBC dilution is still unknown. According to Effros, non-volatile constituents are diluted about 1:12,000 (26)
Contamination of EBC
Contamination of EBC occurs due to possible saliva and oropharingeal content leaking into the sample. Prevention of salivary contamination may be achieved by the use of EBC collectors with a mouthpiece and a two-way non-rebreathing valve.
As saliva contains many specific biomarkers (proteins, lipids, carbohydrates), appropriate measures to prevent its leaking into EBC must be applied (collector selection, periodic swallowing of saliva during collection) (27) . Determination of amylase catalytic concentration in EBC is used to determine the extent of salivary contamination and for rejection of unsuitable specimens of EBC. Bacterial flora from pharingo-oral tract may increase nitrite concentration in EBC (28) . Bacterial contamination should be prevented by mouthwash with chlorhexadine before EBC collection.
Recently, fractionation of exhaled breath was used to reduce the contribution of upper airways (influence of environmental factors on upper airways) and to increase the contribution of bronchial and alveolar tracts on the EBC content, e.g. malondialdehyde (29) .
Sample handling -pre-analytical procedures
Gas standardization of EBC The value of pH is not stable due to the effect of the atmosphere and exhaled CO 2 . On gas standardization, i.e. deareation CO 2 is removed from the sample, thus reducing the effect of CO 2 on pH measurement (30) . Gas standardization may be performed in more ways, e.g. by bubbling argon, partial CO 2 pressure of 5.33 kPa and helium through the EBC samples. pH can be determined in EBC before (31) or after gas standardization (32 (33) . During the procedure of gas standardization of EBC, pH rises to a point at which stable reading is possible. In healthy individuals, pH of gas standardized EBC ranges between 7.4 and 8.8 (34) , and in asthmatics pH ranges between 7.58 and 7.75 before therapy and between 7.67 and 7.91 after the therapy with salbutamol, respectively (35) .
Extraction methods for some analytes from EBC
For chromatographic methods of some analytes in EBC (e.g. leukotrienes), their extraction/concentration is required. These procedures increase analytical sensitivity in the determination of analytes in EBC. These methods include immunoaffinity extraction, IAE (36), solid phase extraction, SPE (37), solvent extraction, SE (38) and lyophylization (39) . IAE include separation of compounds with specific antibodies. By the SPE dissolved or suspended compounds are separated from other compounds in the liquid mixture based to their chemical and physical properties. SE is used to separate components according to their relative solubility in water and organic solvent. These extraction methods are performed for sample purification prior to chromatography analysis. Consequently, they reduce interferents from the EBC matrix that can influence the result. Lyophilization, also known as freeze drying process of dehydratation, may be used for concentrating non-volatile or semi-volatile compounds dissolved in EBC (39) . In that way, EBC may be stored without refrigeration for long period (40) . In addition, process of EBC lyophilisation removes volatile solutes, e.g. NH 3 (41) , which may influence pH or conductivity of EBC. An EBC sample lyophilized and then resuspended gives a 20-fold concentration of biomarkers (42) . Lyophilisation may improve reproducibility in determination of some biomarkers (17) . 
EBC storage

Analytical phase
Analytical methods
Apart from preanalytical issues of EBC, its analysis is very important methodological issue, because conventional assays must be adjusted to very low concentrations of biomarkers in EBC. The problem is more conspicuous in immunoassays, especially in commercial immunoassay kits, that neither are not validated for such low concentrations nor for the matrix of EBC sample (27) . So, these conventional methods are affected by poor sensitivity and specificity.
Usually, methods for the analysis of EBC samples were traditional analytical methods for the analysis of other biological samples, and these methods are scheduled for the single-analyte determination, e.g. pH-metry, biosensors (43) ELISA -enzyme-linked immunosorbent assay; GC -gas chromatography; MS -mass spectrometry; HPLC -high performance liquid chromatography; GC-MS -gas chromatography-mass spectrometry; LC-MS -mass spectrometry; HPLC-MS -high performance liquid chromatography-tandem mass spectrometry; DMS -differential mobility spectrometry; GC-DMS -mass spectrometry-differential mobility spectrometry; ESI-DMS -electrospray ionization-mass spectrometry-differential mobility spectrometry; COPD -chronic obstructive pulmonary disease; CF -cystic fibrosis; OSAobstructive sleep apnea; GERD -gastroesophageal reflux disease; ARDS -acute respiratory distress syndrome; NA -not available. (56) .
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Method optimization/validation
Optimization and validation of conventional methods applied for EBC analysis are problematic, especially for the very low concentrations of biomarkers, since the coefficient of variations (CV) is much higher due to nonlinearity of the assay in that low range (57) . All results in the low range are based on interpolation, and the determination of the lower limit of detection (LOD) and lower limit of quantification (LOQ) are disputable. In addition, validation of analytical methods for EBC analysis depends on the standardization of preanalytical phase. Analysis of EBC by using conventional analytical methods is more useful for qualitative than for quantitative analysis of EBC (46) . Immunoassays are sensitive, but lack in specificity. Conventional techniques must be compared with reference methods, i.e. chromatographic techniques and mass spectrometry, methods that have satisfactory precision, accuracy, LODs, LOQs (58).
Limit of detection and quantification for analytes in EBC
LOD defines the lowest quantity of a substance that can be distinguished from the blank value (zero, absence of particular substance) in the linear range of the assay, where the value of CV is known. LOQ presents the lowest quantity of the substance that can be measured. It is not easy to define the LODs and LOQs of EBC constituents, since native EBC sample is extremely diluted solution and most biomarkers are present at very low concentrations. Therefore, LODs and LOQs of EBC constituents depend on the pre-treatment procedures of EBC (preconcentration, i.e. lyophilisation). EBC preconcentration is necessary to improve LODs and LOQs values. In addition, LOD of particular component depends on the method used to determine its value (Table 2 ). In general, spectrophotometric methods and immunoassays have higher detection limits (detection at micromolar levels) than the chromatographic methods (detection at nanomolar and picomolar levels) (Table 2 ) (3,55).
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Data handling
Normalization factor for analytes in EBC To account for the fluctuation of constituents in extremely diluted biological samples, laboratory medicine specialists try to normalize (i.e. adjust) the level of particular analyte using the marker with stable concentration. A normalization factor is defined as the ratio between two analytes in the same body fluid. Some authors (26) have tried to develop normalization factor, e.g. concentration of urea, cation concentration and osmolality and conductivity after lyophilisation. As the normalization factor must have the same physical and chemical characteristics (solubility, volatility) as the measured constituent, a universal normalization factor
is not yet defined (59, 60) . Urea might be the normalization factor to control intra-individual variability of different analytes in EBC samples (59, 60) .
Post-analytical phase
EBC is a matrix that contains large number of mediators that can be used as biomarkers of respiratory diseases. Biochemical biomarkers in EBC are indicators of health condition or indicators of a pathogenic biological process in respiratory system, particularly in lower respiratory tract. The interpretation of the values of the particular biomarker or biomarkers pattern in EBC samples is the final goal of EBC analysis. Laboratory medicine specialists and clinicians have to co-operate in this field of science. Values of EBC constituents have been extensively investigated in healthy subjects as well as in patients with respiratory diseases, since these diseases are associated with alterations of the RTLF composition (59) . (77, 78) .
Reference values for key biomarkers in EBC
Determination of reference values of particular analytes in EBC and selection of different disease-related biochemical biomarkers are integral part of post-analytical phase of the EBC analysis (Table 1,  Table 3 ). However, reference values for EBC constituents are not established, since some analytical problems are not solved. Concentrations of some biomarkers in EBC obtained in healthy subjects, adults and children, are presented in Table 3 . These values derived from the literature data in investigations of biomarkers in patients with respiratory diseases, where healthy subjects had participated as control groups. Future studies are needed to establish the reference values of EBC biomarkers (79) .
Clinical use and interpretation of biomarkers in respiratory diseases
A number of investigations study the changes of biomarkers in different pulmonary diseases (Table  1 , Table 4 ). The list of states and diseases for which EBC analysis is used include asthma (2, 3, 17, 44, 69, 73, 74, 77, 89, 90, 95) , COPD (2, 3, 42, 47, 54, (71) (72) (73) 77, 83, 86, 96) , gastroesophageal reflux disease (GERD) (2, 3, 45) , obstructive sleep apnea (OSA) (80, 94) , pulmonary fibrosis (81) , pneumonia (4, 17) , cystic fibrosis (7, 17, 76, 92) , adult respiratory distress syndrome (ARDS) (3, 17, 93) , non-respiratory diseases (82, 84) ( Table 1) . Increased values of H 2 O 2 in EBC were found in healthy smokers (17) , in patients with asthma (19, 60) , COPD (17, 93) , cystic fibrosis (7) bronchiectasis (17), ARDS (17) , as well as in non-respiratory disease, e.g. systemic sclerosis (84) . In addition, day to day intra-subject CV of 43% in healthy subjects has been reported (85).
Significant decrease in EBC pH has been reported in patients with acute exacerbation of asthma (17) and in COPD (86) . The term 'acid stress' describes a shift in pH toward the more acid values (87) . In asthmatics, pH returned back higher values after successful anti-inflammatory treatment with steroids (17, 60) . Furthermore, pH levels were related to eosinophilic (in asthmatics) or neutrophilic (in patients with COPD) inflammation of the airways (19) .
Concentrations of NO and NO-related compounds were found to be significantly higher in asthma (63) . In patients with COPD, literature data of nitrite/nitrate levels are not consistent. Some studies have indicated increased levels (88) , and some studies reported unchanged levels of nitrite/nitrate in comparison with healthy controls (62) . Children with CF are reported to have decreased levels of NO and increased levels of nitrite in EBC (63) . It seems that NO production in these patients is trapped by mucus in the airways. Therefore, the determination of nitrite might be a better biomarker of NO production in patients with CF.
Leukotrienes, Cys-LTs and LTB 4, were reported to be increased in asthmatic patients as compared with healthy subjects (89) . Prostaglandine PGE 2 levels were found to be increased in EBC in patients with COPD (83) . In these patients, LTB 4 increased in the stable state. During exacerbation, the concentration of LTB 4 was markedly higher than in the stable phase of disease, and after antibiotic treatment LTB 4 levels were decreased (71) . In patients with CF concentration of LTB 4 were increased (76).
8-isoprostane concentration was found to be elevated in asthma (90) , COPD (83), interstitial lung disease (91), CF (92), ARDS (93), OSA (94) . In patients with acute exacerbation of asthma or COPD, 8-isoprostane concentrations were found to be decreased after anti-inflammatory medications (17) .
Concentrations of interleukins are changed in some pulmonary diseases in comparison with healthy subjects, e.g. IL-4 levels were increased, and interferon-γ levels were decreased in ascthmatic subjects (95) . Furthermore, medication with steroids resulted with decrease of IL-4 and increase of interferon-γ concentration. Concentrations of IL-6 were increased in patients with OSA (94), COPD (96), CF (76), lung cancer patients (97) , and in cigarette smokers (98) ( Table 4) .
Outlook
We must be aware that EBC analysis is still used as a research tool only. Limitations referred to pre-an- COPD -chronic obstructive pulmonary disease; CF -cystic fibrosis; GER -gastroesophageal reflux; GERDgastroesophageal reflux disease; FeNO -fractional exhaled nitric oxide; FEV1 -forced exhaled volume in 1 second;↑ -increased, ↓ -decreased, ↔ -no difference, not detectable or absence; NA -not available. alytical, analytical and post-analytical phases of EBC analysis are numerous. The major limitation is enormous dilution of the RTLF, and consequently, low concentrations of EBC constituents, with detection levels close to the limits of analytical methods. Furthermore, methods for single-analyte determinations lack in sensitivity. Today, the interpretation of the results obtained is somewhat doubtful since reference values are not established. Therefore, research and standardization of all the phases of the analytical process should be continued to allow appropriate interpretation of the results obtained. The application of multi-analyte EBC analysis in the field of metabonomics, proteomics, and genomics (99,100) has not been fully explored. Metabolomic/metabonomic based analyses of EBC have shown the possibility to discriminate between healthy and asthmatic subject, and furthermore to characterize asthma sub-phenotypes. Some efforts are made to investigate DNA as a biomarker for lung diseases (2) . However, the results are dissonant, since some authors have detected DNA, and some authors failed to detect DNA in EBC. Our attempt to detect DNA in EBC was unsuccessful, too.
Hopefully, when all pre-analytical, analytical and post-analytical requirements are met, EBC biomarkers can be selected, and EBC analysis can be used in clinical practice, in the diagnosis and, even in the longitudinal follow-up of patients (monitorig of therapy effects), resulting in better outcome of disease.
